Molecular Formula: C23H27FN4O3
Molecular weight: 426.5 g/mol
CAS No: 144598-75-4
ATC Code: N05AX13
Drug Class: Anti-Psychotic
General Properties:
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug’s therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.
Paliperidone is an Atypical Antipsychotic.
Indication:
Paliperidone is used to treat the symptoms of psychotic (mental) disorders, including schizophrenia. It may also be used alone or together with other medicines to treat patients with schizoaffective disorder. This medicine should not be used to treat behavioral problems in older adult patients who have dementia.
